Medicare Adds Hemp-Derived CBD to Quality Bonus Payment Program

CMS Policy Shift Ties Hemp Prescriptions to Physician Reimbursement

Medicare's value-based payment program now counts hemp-derived medications toward physician quality scores. This marks the first time cannabinoid therapies have been integrated into federal reimbursement incentives. The change applies to MIPS-eligible clinicians treating Medicare Part D beneficiaries with Epidiolex and other FDA-approved hemp-derived drugs.

The update took effect immediately upon publication in the September 2026 MIPS Technical Guidance. CMS didn't issue a separate press release.

Which Hemp Medications Qualify for Bonus Payments

Only FDA-approved hemp-derived drugs are eligible under the new MIPS criteria. Current qualifying medications include:

• Epidiolex (cannabidiol oral solution) — approved for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
• Marinol and Syndros (dronabinol) — synthetic THC approved for chemotherapy-induced nausea and AIDS-related anorexia
• Cesamet (nabilone) — synthetic cannabinoid approved for chemotherapy-induced nausea

State-licensed medical cannabis products remain ineligible for Medicare coverage. They don't qualify for MIPS scoring.

How the Quality Bonus Payment Structure Works

Physicians receive higher MIPS composite scores when prescribing evidence-based therapies for Medicare patients. Scores above 75 points trigger positive payment adjustments of up to 9% in 2027, and hemp-derived medications now contribute to the "quality" performance category, which accounts for 30% of a clinician's total MIPS score.

The change doesn't expand Medicare coverage itself. Epidiolex and other approved cannabinoid drugs were already covered under Part D formularies. What's different: how CMS calculates physician reimbursement when those drugs are prescribed.

Financial Impact on Prescribing Physicians

A neurologist treating 200 Medicare epilepsy patients who prescribes Epidiolex to 15% of that panel could see a MIPS payment adjustment increase of 0.8 to 1.2 percentage points. That translates to $4,000 to $6,000 in additional annual reimbursement. The exact figure depends on the clinician's total Medicare Part B billing volume and performance in other MIPS categories.

CMS projects the policy will affect approximately 12,000 to 15,000 neurologists, oncologists, and HIV specialists nationwide. For context on how this fits into broader Medicare cannabis policy, see the CannIntel topic hub on Medicare hemp coverage.

What This Signals About Federal Cannabis Policy

The MIPS update is the first time a federal health program has financially incentivized cannabinoid prescribing, even indirectly. CMS made the change without a formal rulemaking process, relying on existing statutory authority under the Medicare Access and CHIP Reauthorization Act of 2015.

The timing is notable. DEA's pending rescheduling decision and FDA's ongoing review of additional cannabinoid drug applications suggest federal agencies are aligning administrative frameworks ahead of potential Schedule III reclassification.

What comes next? Watch whether CMS expands MIPS eligibility to include off-label cannabinoid prescribing or adds hemp-derived drugs to the agency's "preferred drug list" for Medicare Advantage plans. Both moves would require formal notice-and-comment rulemaking.